Human, pig, and chicken versions of cathelicidin antimicrobial peptides kill bacteria through distinct mechanisms and have separable antibacterial and immune-modulating activities.
Antibacterial ≠ immunomodulatoryShorter PMAP-36 analogs needed to form pairs (dimers) for immune modulation but not for bacterial killing — these are independently engineerable functions
What the researchers found
Three cathelicidin antimicrobial peptides from different species — pig (PMAP-36), human (LL-37), and chicken (CATH-2) — kill E. coli bacteria through fundamentally different mechanisms despite being structurally similar peptides. Transmission electron microscopy revealed distinct killing patterns for each peptide.
Surprisingly, LL-37 binds bacterial endotoxin (LPS) very weakly compared to PMAP-36, yet it was the most potent at blocking LPS activation of immune cells (macrophages). This means strong LPS binding doesn't necessarily predict strong immunomodulatory activity.
Structure-activity analysis of PMAP-36 revealed that the first 11 amino acids at the N-terminal end could be removed without affecting bacterial killing, LPS neutralization, or binding. Cutting 4 more amino acids, however, dramatically reduced all activities. Shorter PMAP-36 analogs required dimerization (pairing up) for immunomodulatory function but not for bacterial killing — indicating these are separable activities.
Why it matters
As antibiotic resistance grows, host defense peptides (cathelicidins) are being studied as potential alternatives. This research matters because it shows that similar-looking antimicrobial peptides can work through completely different mechanisms — meaning scientists can't simply assume one cathelicidin will behave like another. The finding that antibacterial and immunomodulatory activities can be separated opens the door to engineering peptides optimized for specific therapeutic goals.
The numbers in context
3 cathelicidins compared · E. coli killing model · First 11 amino acids dispensable for PMAP-36 activity · Dimerization required for short analogs' immunomodulation · LPS binding ≠ LPS neutralization capacity
How the study worked
Researchers compared three cathelicidins (pig PMAP-36, human LL-37, chicken CATH-2) and several PMAP-36 truncation analogs using multiple in vitro assays. Transmission electron microscopy visualized bacterial killing mechanisms. LPS binding and neutralization were measured separately. Macrophage activation assays (using RAW 264.7 cells) assessed immunomodulatory capacity. Monomer vs dimer forms of the peptides were tested to determine which structural form was needed for each function.
Who was studied
In vitro study using E. coli bacteria and RAW 264.7 mouse macrophage cells
What this study cannot tell us
This is entirely an in vitro study — effects in a test tube may differ from what happens inside a living organism. Only E. coli was tested as a target bacterium; activity against other pathogens may differ. The immunomodulatory assays used a mouse macrophage cell line (RAW 264.7), which may not perfectly reflect human immune responses.
How to read the evidence
This is a preliminary-grade in vitro study using bacterial cultures and a mouse cell line. While the mechanistic insights are valuable, no animal or human data supports the findings, and only one bacterial species was tested.
When this study was published
Published in 2019 in Scientific Reports, this is a relatively recent study that reflects the current state of cathelicidin structure-activity research and contributes to the growing field of peptide antibiotic design.
The bigger picture
As traditional antibiotics fail against resistant bacteria, antimicrobial peptides are increasingly studied as alternatives. This research provides crucial design principles: cathelicidins are not interchangeable, their dual functions (killing and immune modulation) can be independently optimized, and minimal active fragments can be identified. These insights feed directly into the rational design of next-generation peptide antibiotics.
Questions still open
- Can PMAP-36 truncation analogs be further optimized into viable antibiotic candidates with reduced toxicity?
- Do these different killing mechanisms translate to different resistance profiles — could bacteria become resistant to one cathelicidin but not another?
- Would combining cathelicidins with different killing mechanisms produce synergistic antibacterial effects?
Common questions
What are cathelicidins and why are they important?
Why does it matter that these peptides kill bacteria differently?
Read the original research
Cathelicidins PMAP-36, LL-37 and CATH-2 are similar peptides with different modes of action.
Scientific reports, 9(1), 4780
Citation
Scheenstra, Maaike R; van den Belt, Matthias; Tjeerdsma-van Bokhoven, Johanna L M; Schneider, Viktoria A F; Ordonez, Soledad R; van Dijk, Albert; Veldhuizen, Edwin J A; Haagsman, Henk P. (2019). Cathelicidins PMAP-36, LL-37 and CATH-2 are similar peptides with different modes of action.. Scientific reports, 9(1), 4780. https://doi.org/10.1038/s41598-019-41246-6